Fig. 1

PFKFB4 gene is gradually up-regulated with the development of cytokine release syndrome in CAR T-cell therapy. A–C Volcano plot of CRS grade-related differentially expressed genes between the different groups. Fold Change > 1.5 and p-value < 0.05 were set as screening criteria. Genes that have both a significant p-value (lower than 0.05) and a fold change (higher than 1.5) are represented as red dots. Genes that either have a significant p-value (lower than 0.05) or a fold change (higher than 1.5) are represented as blue and green dots. Gray dots mean genes neither have a significant p-value nor fold change. PFKFB4 gene expression in CD22 CAR T-cell (D) and CD19 CAR T-cell products (E) based on different CRS grade group